drugset / Trial / NCT01483248

Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis

NCT01483248

RandomizedSingle-groupOpen-labelTreatment

Summary

Orthotopic liver transplantation (OLT) is currently the most effective method for end-stage liver diseases. However, the critical shortage of donor organs, high cost, and the problem of immune rejection limit its clinical application, and even some patients on the waiting list will never survive to receive a matched liver. Stem cell transplantation instead of conventional medical therapy or orthotopic liver transplantation will be a promising alternate approach to regenerate damaged hepatic mass. Adult mesenchymal stem cells (MSCs) are generally thought of as an autologous source of regenerative cells in previous studies.In this study, the safety and efficacy of menstrual blood-derived stem cells transplantation for patients with liver cirrhosis will be evaluated.

Timeline

Start
2010-10
Primary completion
2013-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MenSCs Cell therapy 1e+06 cells/kg Intravenous
Comparator Ursodeoxycholic Acid Small molecule
Comparator interferon alfa-2b Protein / enzyme biologic

Indications